Drug makers seek to set record straight on GLP-1, DPP-4 pancreatic findings
This article was originally published in Scrip
Executive Summary
The only way to ever really get to the bottom of whether so-called incretin mimetic therapies – glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors – trigger pancreatitis and precancerous cellular changes in patients with Type II diabetes will be to conduct adequately powered, long-term epidemiological studies, according to Dr Solomon Iyasu, director of the FDA's Division of Epidemiology.